Fresh analysis reveals that patients who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight much more quickly than those who halt traditional lifestyle plans.
Published data in a major medical journal shows that while overweight individuals can lose a large proportion of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these medications need to be informed of the potential of fast weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
That rate of recovery means a return to starting mass in about one and a half years.
Analyzing Approaches
The analysis, which looked at dozens of studies involving over 9,000 of participants, compared the effects of the injectable medications with conventional dieting.
Scientists note that individuals who shed pounds through lifestyle changes alone usually see a more gradual weight regain—around 0.1 kg a month—once they finish.
Explaining the Quick Regain
Nutrition scientists propose the mode of action of the injections is key to understanding the accelerated rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is uncontrolled, making binge eating far more likely."
A Lifelong Disease?
The NHS recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals contend that, due to the high risk of weight regain, the therapy should be considered life-long.
This opinion is reinforced by drug manufacturers, who note that the findings "underscore the chronic nature of obesity," akin to managing conditions like high blood pressure.
User Accounts
Users who have discontinued the jabs report a intense resurgence of cravings.
"I experienced something activating and you're instantly extremely hungry," described a patient.
The struggle is worsened if users have not established lasting dietary or behavioural modifications during therapy.
Growing Interest
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and long-term success hinges on integrated lifestyle management.
